The UK healthcare scene is excited with talk of Retatrutide, a novel dual GIP and GLP-1 receptor offering remarkable potential for weight management. Initially, it's unavailable to the NHS but is emerging as increasingly desirable amongst individuals wanting successful fat reduction strategies. A number of providers are already supplying access to,